NASDAQ-GS · traded in Congress
Arcutis Biotherapeutics, ARQT
$25.55 -1.45 (-5.37%) Nov 6, 2026
Market value$3.2B
P/E ratio-
Analyst target$40.00
52-week range-
Avg volume2,664,918
Dividend yieldN/A
Chart
Analyst ratings
- 7 buy
- 1 hold
- 0 sell
Low target$34.00
Average target$40.38
High target$48.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $144M | - | $9M | 6.1% | |
| $130M | - | $15M | 11.6% | |
| $105M | - | $-11M | -10.7% | |
| $130M | - | $17M | 13.4% |
Congress trades in ARQT
Members of Congress disclosed 2 transactions in ARQT in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 05/29/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 6/8/2026 filing |
| 03/03/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 4/7/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
